NL6409714A
(ja)
*
|
1962-10-30 |
1965-10-01 |
|
|
US3472848A
(en)
*
|
1966-11-17 |
1969-10-14 |
Merck & Co Inc |
3-hydroxy and 3-mercapto-pyrazinoyl-guanidines,corresponding ethers and thioethers and processes for their preparation
|
US3948895A
(en)
*
|
1971-09-28 |
1976-04-06 |
E. I. Du Pont De Nemours And Company |
Synthesis of 3,5-diaminopyrazinoic acid from 3,5-diamino-2,6-dicyanopyrazine and intermediates
|
US4085211A
(en)
*
|
1975-12-15 |
1978-04-18 |
Merck & Co., Inc. |
Pyrazinecarboxamides and processes for preparing same
|
US4087526A
(en)
*
|
1976-07-23 |
1978-05-02 |
Merck & Co., Inc. |
(3-Amino-5-substituted-6-fluoropyrazinoyl or pyrazamido)-guanidines and their derivatives bearing substituents on the guanidino nitrogens
|
US4208413A
(en)
*
|
1977-03-04 |
1980-06-17 |
Merck & Co., Inc. |
N-Pyrazinecarbonyl-N'-alkoxycarbonyl and N',N"-bis(alkoxycarbonyl)guanidines and processes for preparing same
|
US4108859A
(en)
*
|
1977-06-06 |
1978-08-22 |
The Dow Chemical Company |
Microbicidal (pyridinylamino) alkyl guanidines
|
US4140776A
(en)
*
|
1977-09-16 |
1979-02-20 |
Merck & Co., Inc. |
N-pyrazinecarbonyl-N'-acylguanidines
|
US4190655A
(en)
*
|
1978-08-28 |
1980-02-26 |
Merck & Co., Inc. |
Amiloride citrate
|
EP0009054A1
(en)
*
|
1978-09-19 |
1980-04-02 |
Merck & Co. Inc. |
N-Pyrazinecarbonyl-N'-substituted-sulfamoyl-guanidine and processes for preparing same
|
US4246406A
(en)
*
|
1979-03-27 |
1981-01-20 |
Merck & Co., Inc. |
Heterocyclic substituted pyrazinoylguanidines
|
US4224447A
(en)
*
|
1979-03-27 |
1980-09-23 |
Merck & Co., Inc. |
Novel pyrazinecarboxamides and processes for preparing same
|
US4362724A
(en)
*
|
1980-05-19 |
1982-12-07 |
Merck & Co., Inc. |
Method of treating edema and hypertension and pharmaceutical composition therefor in which the active ingredient comprises a novel substituted pyrazinyl-1,2,4-oxadiazole and a kaliuretic diuretic
|
US4309540A
(en)
*
|
1980-05-19 |
1982-01-05 |
Merck & Co., Inc. |
Substituted pyrazinyl-1,2,4-oxadiazoles
|
US4454132A
(en)
*
|
1981-03-16 |
1984-06-12 |
Merck & Co., Inc. |
Pharmaceutical compositions of novel substituted pyrazinyl-1,2,4-oxadiazoles useful in the treatment of edema and hypertension
|
US4510322A
(en)
*
|
1981-07-13 |
1985-04-09 |
Merck & Co., Inc. |
Indacrinone having enhanced uricosuric
|
US4663322A
(en)
*
|
1982-01-04 |
1987-05-05 |
Beyer Jr Karl H |
Antihypertensive hyperuretic and saluretic agent combinations
|
US4952582A
(en)
*
|
1982-01-04 |
1990-08-28 |
Beyer Jr Karl H |
Pyrazinoylguanidine and derivatives thereof having few polar substituents and being useful as hyperuretic agents
|
DE3312516A1
(de)
*
|
1983-04-07 |
1984-10-11 |
Brigitte Dr. 7400 Tübingen Pfeiffer |
Kernsubstituierte phenylalkylenguanidinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
|
US4604394A
(en)
*
|
1984-10-01 |
1986-08-05 |
Merck & Co., Inc. |
Antiarrhythmic compositions and method
|
DE3925847A1
(de)
*
|
1989-08-04 |
1991-02-07 |
Huels Chemische Werke Ag |
Verfahren zur herstellung von 3-aminopyrazin-2-carbonsaeuremethylester
|
US5304125A
(en)
*
|
1990-10-05 |
1994-04-19 |
The University Of North Carolina |
Apparatus for administering solid particulate aerosols to the lungs
|
KR930701992A
(ko)
*
|
1990-10-05 |
1993-09-08 |
웨인 알.조운즈 |
환자의 폐에 잔존하는 점액 분비물의 제거 방법
|
TW213903B
(ja)
*
|
1991-08-16 |
1993-10-01 |
Boehringer Ingelheim Kg |
|
US6169107B1
(en)
|
1993-04-28 |
2001-01-02 |
Sumitomo Pharmaceutical Co., Ltd. |
Indoloylguanidine derivatives
|
DE4337609A1
(de)
*
|
1993-11-04 |
1995-05-11 |
Boehringer Ingelheim Kg |
Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
|
US5656256A
(en)
*
|
1994-12-14 |
1997-08-12 |
The University Of North Carolina At Chapel Hill |
Methods of treating lung disease by an aerosol containing benzamil or phenamil
|
TW372967B
(en)
*
|
1994-12-27 |
1999-11-01 |
Kanebo Ltd |
1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof
|
US5635160A
(en)
*
|
1995-06-07 |
1997-06-03 |
The University Of North Carolina At Chapel Hill |
Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
|
US5628984A
(en)
*
|
1995-07-31 |
1997-05-13 |
University Of North Carolina At Chapel Hill |
Method of detecting lung disease
|
US5801177A
(en)
*
|
1995-12-14 |
1998-09-01 |
Beyer, Jr.; Karl H. |
Method for controlling and/or lowering serum glucose and fatty acid concentrations and hypertensive blood pressure in non-insulin-dependent diabetic patients
|
US5877217A
(en)
*
|
1995-12-26 |
1999-03-02 |
Alteon Inc. |
N-acylaminoalkyl-hydrazinecarboximidamides
|
JP2001513568A
(ja)
*
|
1997-08-29 |
2001-09-04 |
ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル |
肺疾患を治療するためのウリジン5’−ジホスフェートとその類似体の使用
|
EP1143896B1
(en)
*
|
1998-10-20 |
2006-12-13 |
The University of North Carolina at Chapel Hill |
Methods of hydrating the nasal mucosal surface
|
AU2740500A
(en)
*
|
1999-01-29 |
2000-08-18 |
Beyer, Camille F. |
Composition and method for treating diabetes
|
MXPA02000684A
(es)
|
1999-07-19 |
2003-07-21 |
Univ North Carolina |
Conjugados de bloqueadores del canal de sodio y metodos de uso de los mismos.
|
EP1595540A1
(en)
|
2000-11-21 |
2005-11-16 |
Sankyo Company Limited |
Composition containing an angiotensin II receptor antagonist and a diuretic and its use for the treatment of hypertension
|
US6858614B2
(en)
|
2002-02-19 |
2005-02-22 |
Parion Sciences, Inc. |
Phenolic guanidine sodium channel blockers
|
US6858615B2
(en)
|
2002-02-19 |
2005-02-22 |
Parion Sciences, Inc. |
Phenyl guanidine sodium channel blockers
|
US7704995B2
(en)
*
|
2002-05-03 |
2010-04-27 |
Exelixis, Inc. |
Protein kinase modulators and methods of use
|
AU2003234464B2
(en)
*
|
2002-05-03 |
2009-06-04 |
Exelixis, Inc. |
Protein kinase modulators and methods of use
|
ES2362998T3
(es)
|
2002-08-19 |
2011-07-18 |
Pfizer Inc. |
Terapia de combinación para enfermedades hiperproliferativas.
|
US6903105B2
(en)
*
|
2003-02-19 |
2005-06-07 |
Parion Sciences, Inc. |
Sodium channel blockers
|
CA2529949C
(en)
*
|
2003-06-26 |
2013-08-06 |
Biotron Limited |
Antiviral compounds and methods
|
AU2004248859C1
(en)
*
|
2003-06-26 |
2011-11-24 |
Biotron Limited |
Antiviral acylguanidine compounds and methods
|
US7326706B2
(en)
*
|
2003-08-15 |
2008-02-05 |
Bristol-Myers Squibb Company |
Pyrazine modulators of cannabinoid receptors
|
US20050090505A1
(en)
*
|
2003-08-18 |
2005-04-28 |
Johnson Michael R. |
Methods of reducing risk of infection from pathogens
|
DK1663235T3
(da)
*
|
2003-08-18 |
2013-10-28 |
Parion Sciences Inc |
Beskyttede pyrazinoylguanidin-natriumkanal-blokkere
|
AU2004271945A1
(en)
*
|
2003-08-18 |
2005-03-24 |
Parion Sciences, Inc. |
Aliphatic pyrazinoylguanidine sodium channel blockers
|
US7745442B2
(en)
|
2003-08-20 |
2010-06-29 |
Parion Sciences, Inc. |
Methods of reducing risk of infection from pathogens
|
US20090253714A1
(en)
*
|
2003-08-20 |
2009-10-08 |
Johnson Michael R |
Methods of reducing risk of infection from pathogens
|
US20070099968A1
(en)
*
|
2004-06-26 |
2007-05-03 |
Biotron Limited |
Antiviral compounds and methods
|
US20070021439A1
(en)
*
|
2005-07-25 |
2007-01-25 |
Parion Sciences, Inc. |
Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
CA2630920A1
(en)
*
|
2005-11-22 |
2007-05-31 |
University Of South Florida |
Inhibition of cell proliferation
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
CN101663262B
(zh)
|
2006-12-01 |
2014-03-26 |
百时美施贵宝公司 |
用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
|
AU2008310734B2
(en)
|
2007-10-10 |
2014-06-05 |
Parion Sciences, Inc. |
Delivering osmolytes by nasal cannula
|
JP5611844B2
(ja)
|
2008-02-26 |
2014-10-22 |
パリオン・サイエンシィズ・インコーポレーテッド |
多環芳香族ナトリウムチャネル遮断薬
|
DE102008053024B4
(de)
|
2008-10-24 |
2015-04-30 |
RUHR-UNIVERSITäT BOCHUM |
Verwendung von Amilorid-Derivaten zur Bekämpfung von Insekten und Milben
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
US8945605B2
(en)
|
2011-06-07 |
2015-02-03 |
Parion Sciences, Inc. |
Aerosol delivery systems, compositions and methods
|
AR086745A1
(es)
|
2011-06-27 |
2014-01-22 |
Parion Sciences Inc |
3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
|
WO2013003444A1
(en)
|
2011-06-27 |
2013-01-03 |
Michael Ross Johnson |
A chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
|
AU2013267504B2
(en)
|
2012-05-29 |
2017-11-02 |
Parion Sciences, Inc. |
Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
|
NZ709197A
(en)
|
2012-12-17 |
2020-06-26 |
Parion Sciences Inc |
3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds
|
MX2015007796A
(es)
|
2012-12-17 |
2015-09-04 |
Parion Sciences Inc |
Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales.
|
EP2986599A1
(en)
|
2013-04-17 |
2016-02-24 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
EP3019492B1
(en)
*
|
2013-07-08 |
2017-09-06 |
Boehringer Ingelheim International GmbH |
Amiloride-type compounds as inhibitors in epithelial sodium channels for the treatment of diseases of the lungs and airways
|
US9102633B2
(en)
|
2013-12-13 |
2015-08-11 |
Parion Sciences, Inc. |
Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
EP3495348A4
(en)
|
2016-07-29 |
2020-01-22 |
Toray Industries, Inc. |
GUANIDINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES
|
CA3125765A1
(en)
|
2019-01-18 |
2020-07-23 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|